Suchergebnisse - "Mahévas, Matthieu"

PubPharm (6)

1

Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia

enthalten in: Science translational medicine | 2021

von Crickx, E. | Chappert, P. | Sokal, A. | +16

2

Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France

enthalten in: American journal of hematology | 2015

von Moulis, G. | Lapeyre-Mestre, M. | Mahévas, M. | +2

CommentIn: Am J Hematol. 2015 Apr;90(4):271-2. - PMID 25677795

3

Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia

enthalten in: American journal of hematology | 2013

von Mahévas, M. | Ebbo, M. | Audia, S. | +9

4

Preferential splenic CD8(+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia

enthalten in: Blood | 2013

von Audia, S. | Samson, M. | Mahévas, M. | +20

5

B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells

enthalten in: The Journal of clinical investigation | 2013

von Mahévas, M. | Patin, P. | Huetz, F. | +16

6

Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia

enthalten in: Blood | 2012

von Patel, V. | Mahévas, M. | Lee, S. | +15

1
[1]